医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FUJIFILM SonoSite Showcases the First High-Resolution Imaging Kiosk, the X-Porte™, at RSNA 2013

2013年12月02日 AM01:25
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

FUJIFILM SonoSite's X-Porte Ultrasound Kiosk (Photo: Business Wire)FUJIFILM SonoSite’s X-Porte Ultrasound Kiosk (Photo: Business Wire)

View and Share Photo

Close Window


BOTHELL, Wash.

FUJIFILM SonoSite Inc., the world leader in point-of-care (POC) ultrasound, will showcase its high-resolution ultrasound kiosk, the X-Porte™, at the 99th annual meeting of the Radiological Society of North America (RSNA) in Chicago, IL. FUJIFILM SonoSite Inc. delivers highly-innovative tools specifically intended to increase access to ultrasound visualization for patients.

FUJIFILM SonoSite's X-Porte Ultrasound Kiosk (Photo: Business Wire)

FUJIFILM SonoSite’s X-Porte Ultrasound Kiosk (Photo: Business Wire)

X-Porte was designed to cure side-lobe imaging artifacts, through a new type of technology never before used in an ultrasound system: SonoSite’s proprietary Extreme Definition ImagingTM (XDI). XDI is a new beam forming algorithm that significantly reduces the visual clutter from side-lobes that affect all ultrasound products regardless of system size. The resulting ultrasound image appears cleaner with optimal tissue differentiation.

“The overarching goal was to create a high-resolution imaging kiosk that is also delightful to use. This design intent allows clinicians to efficiently use ultrasound anywhere in the hospital it is needed,” said Kevin Goodwin, president and CEO, Fujifilm SonoSite, Inc. “With X-Porte’s advanced signal processing capabilities and multi-gesture touch screen, I believe that we have achieved this objective.”

The technological innovations are a result of the feedback and experiences of hundreds of clinicians that were observed during the development of the ultrasound kiosk. The FUJIFILM SonoSite engineering team was tasked with taking the feedback and combining it with inspiration from the world of consumer electronics to build a system that offers superior image quality in a highly innovative kiosk design. For this reason, X-Porte represents an entirely new way to access and deliver high-resolution ultrasound.

To experience X-Porte, please visit http://rsna.fujimed.com to register for a product demonstration at RSNA. For every product demonstration registered online, Fujifilm will donate $25 to the National Breast Cancer Foundation. For more information, please visit http://www.sonosite.com/.

About Fujifilm

FUJIFILM SonoSite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. The company was among the top 10 companies around the world granted U.S. patents in 2012, and in the year ended March 31, 2013, had global revenues of $26.7 billion*. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

* At an exchange rate of 83 yen to the dollar.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131201005042/en/

CONTACT

Fujifilm
Lauren Geloso, (914) 789-8303
lgeloso@fujifilm.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表